IRVINE, Calif., Jan. 18, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM ® VOLUX™ XC. The long-lasting ...
Patients interested in learning more about JUVÉDERM ® VOLUMA ® XC for temple hollowing are encouraged to enroll in Allē, the Allergan Aesthetics loyalty rewards program. In serving more than seven ...
JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif., Aug. 3, 2022 /PRNewswire/ -- Today, Allergan ...
At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
The FINANCIAL — Allergan plc, on June 1 announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLBELLA XC, for use in the lips for lip ...
Juvéderm Volux XC is an injectable gel filler containing hyaluronic acid. The Food and Drug Administration (FDA) has approved Juvéderm ® Volux ™ XC for the improvement of jawline definition in ...
Consumers and new patients who receive aesthetic treatment from the JUVÉDERM ® Collection of Fillers, can also enroll in Allē, the Allergan Aesthetics loyalty rewards program to unlock access to ...
JUVÉDERM ® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION Commonly reported side effects in the clinical study included ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback